SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about press release

11 Jun 2026 Evaluate
Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg. The Company has enclosed its press release.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

744.75 9.75 (1.33%)
12-Jun-2026 13:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.95
Dr. Reddys Lab 1273.00
Cipla 1393.40
Zydus Lifesciences 1102.45
Lupin 2281.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: